New hope for kids with tough cancers: trial tests personalized immune cell treatment
NCT ID NCT04837547
Summary
This early-stage study is testing a new, personalized treatment for children with two aggressive cancers: recurrent neuroblastoma or a newly diagnosed brain stem tumor called DIPG. Doctors create a custom treatment using the patient's own immune cells and tumor material, aiming to train the body to fight the cancer. The main goal is to see if this combined approach is safe and feasible to produce for young patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Children's Hospital
Charlotte, North Carolina, 28204, United States
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania, 17033, United States
-
University of Florida
Gainesville, Florida, 32611, United States
Conditions
Explore the condition pages connected to this study.